Study Of Diabetic Nephropathy With Atrasentan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5107 participants.

Also called NCT01858532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,107 participants (enrolled count) (from the registry)
Sponsor
  • AbbVie Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01858532
  • EudraCT 2012-005848-21
Other papers using this trial's data
  • Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Lancet (London, England), 2019-05-11 DOI, PubMed 30995972 PubMed links an erratum for this paper. Erratum: PMID 31084966
  • Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure JACC. Heart failure, 2022-07 DOI, PubMed 35772861
  • Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease Clinical pharmacology and therapeutics, 2021-06 DOI, PubMed 33338269, PMC8246733 In the PMC Open Access subset under CC BY-NC.
  • Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease Kidney international, 2023-12 DOI, PubMed 37657768
  • Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial Diabetologia, 2025-03 DOI, PubMed 39661119
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial Clinical journal of the American Society of Nephrology : CJASN, 2021-12 DOI, PubMed 34853062, PMC8729501 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01858532. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-17 (actual); primary completion 2018-03-29 (actual). Results posted on 2019-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Of Diabetic Nephropathy With Atrasentan
Acronym
SONAR
Condition
Diabetic Nephropathy
Intervention (Drug)
Atrasentan
Intervention (Drug)
Placebo
Lead sponsor
AbbVie (class: industry)

Record details

Record id
cardio:ct-nct01858532
Content hash
c0ec7c207dfd2d184ba029961bffa9aa51499d83180d617839e2d5fbb11fbc31